Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:09 AM
Ignite Modification Date:
2025-12-25 @ 5:09 AM
NCT ID:
NCT00482027
Eligibility Criteria:
Inclusion Criteria:
* Healthy males and females
* Age at least 18 years on the day of screening and no greater than 50 years on the day of vaccination
* Available for follow-up for the planned duration of the study (screening plus 12 months)
* Able to give written informed consent;
* No reported high-risk behavior for HIV (Appendix C), willing to undergo HIV testing and receive results;
* If sexually active, willing to use or have partner use condoms from screening until at least 4 months after the vaccination. Additional means of contraception are permitted and encouraged.
Exclusion Criteria:
* Clinically relevant abnormality on history or examination including history of immunodeficiency or use of immunosuppressive medication in last 6 months;
* A chronic medical condition or concurrent condition, which, in the opinion of the investigator, would make the volunteer unsuitable for the study.
* Any of the following abnormal laboratory parameters that are mild and judged to be clinically significant by the principal investigator or designee, or moderate, severe, or very severe: hematology (hemoglobin, absolute neutrophil count \[ANC\] absolute lymphocyte count \[ALC\], absolute CD4 count, platelets); urinalysis, clinical chemistry (total bilirubin, creatinine, AST, ALT). Refer to Appendix D for the grading of these laboratory parameters.
* If female, pregnant or planning a pregnancy within 4 months after receiving the vaccine, or lactating;
* Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of vaccination;
* Receipt of other experimental HIV vaccine at any time;
* Receipt of blood transfusion or blood products within 6 months of vaccination;
* Participation in another clinical trial of an investigational product currently or within 12 weeks of vaccination, or expected during participation in this study;
* History of severe local or systemic reaction to vaccination or history of allergic reactions to vaccines;
* Confirmed infection with HIV-1 or HIV-2;
* Positive for hepatitis B (surface antigen), hepatitis C antibodies, or active syphilis (confirmed by treponemal test such as TPHA in addition to non-treponemal test such as RPR) or active tuberculosis.
* Unlikely to comply with protocol.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT00482027
Study Brief:
Protocol Section:
NCT00482027